LivaNova公共 LIVN 深 滬
等待開盤 12-20 09:30:00 美东时间
62.82
+0.740
+1.19%
華盛通- 最 高63.09
- 今 開62.68
- 成交量 133.49万股
- 最 低 62.08
- 昨 收 62.08
- 總市值 34.25亿
- 52周最高 65.5741
- 市盈率 靜 54.22
- 換手率 2.45%
- 52周最低 32.48
- 委 比 -72.30%
- 總股本 5452.57万
- 歷史最高 131.54
- 量 比 2.42
- 振 幅 1.63%
- 歷史最低 23.58
- 每 手 1
- 風險率 7.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
Mizuho Maintains Outperform on LivaNova, Raises Price Target to $72
Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the price target from $70 to $72.
12-17 21:07
LivaNova To Present Eight Posters At AES Highlighting VNS Therapy's Seizure Reduction And Improved Outcomes In Drug-Resistant Epilepsy
Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant EpilepsyLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company,
12-03 22:03
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
LivaNova Announces 2030 Financial Targets, Sees High-Single-Digit-Plus Revenue CAGR; Adjusted Annual Operating Margin Above 20% Over The Next 3-Years, Targeting High Twenties By 2030; EPS CAGR In The Low Double Digits To Mid-Teens; Adjusted Free Cash Flow Conversion Above 80%
Provides 2030 Targets for Revenue and EPS GrowthLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range
11-13 04:30
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
LivaNova Raises FY2025 Adj EPS Guidance from $3.70-$3.80 to $3.80-$3.90 vs $3.75 Est, Company Now Expects FY25 Revenue To Grow Between 8.5%-9.5% (Versus 8%-9% Prior)
LivaNova (NASDAQ:LIVN) raises FY2025 Adj EPS guidance from $3.70-$3.80 to $3.80-$3.90 vs $3.75 analyst estimate..
11-05 19:03
LivaNova Q3 Adj. EPS $1.11 Beats $0.92 Estimate, Sales $357.800M Beat $343.505M Estimate
LivaNova (NASDAQ:LIVN) reported quarterly earnings of $1.11 per share which beat the analyst consensus estimate of $0.92 by 20.78 percent. This is a 23.33 percent increase over earnings of $0.90 per share from the same
11-05 19:00
Inspire Medical cut at Jefferies on GLP-1 uptake, potential rivalry
Shares of Inspire Medical Systems (NYSE:INSP) slipped on Friday after Jefferies downgraded the MedTech player to Hold from Buy, citing multiple headwinds for the company, including potential competiti...
10-25 00:39
Doximity, LivaNova downgraded as Goldman Sachs reviews MedTech and Health IT coverage
Doximity (NYSE:DOCS), a digital platform for medical professionals, and LivaNova (NASDAQ:LIVN), a medical equipment maker, traded lower on Wednesday after Goldman Sachs downgraded the duo as part of a...
10-02 01:57
